OTTAWA – The federal government says an alternative to EpiPens will be available next month for Canadians with life-threatening allergies.
Health Minister Ginette Petitpas Taylor says she has signed an interim order to allow the U.S.-approved Auvi-Q epinephrine auto-injectors to be imported into Canada.
The order is effective for two weeks while approval is sought to extend the order for up to one year.
READ MORE: Health Canada reviewing whether to extend EpiPen expiry dates
Canada has been experiencing shortages of EpiPen and EpiPen Jr. auto-injectors for the past several months. Pfizer Canada has said that it has resumed shipments of EpiPen but that the supply of both EpiPen and EpiPen Jr. continues to be limited while it works to return supply to normal levels.
WATCH: FDA approves first generic version of EpiPen
Auvi-Q, made by Kaleo, has been approved by the U.S. Food and Drug Administration.
Both EpiPen and Auvi-Q deliver the same labelled dose of epinephrine, however, unlike EpiPen, Auvi-Q has a retractable needle as well as an electronic voice instruction system.
- Wegovy now in Canada: Who should (and shouldn’t) use the weight-loss drug
- Abortion is set to be a key U.S. election issue. Which side has momentum?
- Amid bird flu spread, Canada boosts surveillance and testing at border
- N.B. woman must move to Toronto for life-saving lung transplant. She can’t afford to go
Comments